^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Monjuvi (tafasitamab-cxix)

    i
    Other names: MOR208, MOR-00208, XmAb5574, XENP-5574, MOR-208, INCMOR 0208, MOR 00208, XENP5574, XENP 5574, XmAb 5574, XmAb-5574, INCA000585, INCA-000585, MOR 208, MOR00208, INCMOR0208, ICP-B04, ICPB04, ICP B04, INCMOR-0208
    Company:
    Incyte, InnoCare, Knight Therap, Specialised Therap, Xencor
    Drug class:
    CD19 inhibitor
    Related drugs:
    3d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended
    Trial suspension
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)
    7d
    Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma. (PubMed, Int J Clin Oncol)
    For many years, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard first-line treatment for DLBCL; however, pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) has recently emerged as a new treatment option...In addition, agents that have demonstrated efficacy in patients with relapsed or refractory DLBCL-such as the anti-CD19 antibody tafasitamab and immunomodulatory drugs such as golcadomide-are currently under investigation for use in newly diagnosed patients...BsAbs can enable more flexible treatment strategies, including combination regimens with cytotoxic or chemotherapy-free approaches. This review summarizes recent advances and ongoing trials that are investigating novel therapeutic strategies for newly diagnosed DLBCL that may soon be incorporated into clinical practice.
    Review • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
    14d
    VERLen: Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older (clinicaltrials.gov)
    P2, N=71, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Dec 2026 --> Jun 2027
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Monjuvi (tafasitamab-cxix)
    17d
    Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    lenalidomide • Monjuvi (tafasitamab-cxix)
    1m
    J-MIND: To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (clinicaltrials.gov)
    P1/2, N=72, Active, not recruiting, Incyte Biosciences Japan GK | Trial primary completion date: Dec 2026 --> Jul 2025
    Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
    1m
    CUREMZL002: A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    lenalidomide • Inokai (orelabrutinib) • Monjuvi (tafasitamab-cxix)
    1m
    CCTG LY18-A: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Canadian Cancer Trials Group | Recruiting --> Active, not recruiting | N=18 --> 40
    Enrollment closed • Enrollment change
    |
    Venclexta (venetoclax) • cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Columvi (glofitamab-gxbm)
    1m
    Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib) • Monjuvi (tafasitamab-cxix)
    1m
    Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Monjuvi (tafasitamab-cxix)
    1m
    Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • Monjuvi (tafasitamab-cxix)
    2ms
    Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jun 2026 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    2ms
    realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (clinicaltrials.gov)
    P=N/A, N=102, Completed, Incyte Corporation | Recruiting --> Completed | Trial completion date: Aug 2026 --> Jan 2026
    Trial completion • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    lenalidomide • Monjuvi (tafasitamab-cxix)